To evaluate and compare the effects or oral and transdermal estrogen replacement therapy on biochemical markers of bone resorption in early postmenopausal women.
Design
Controlled, randomized group comparison.
Setting
Outpatient clinic for menopausal women and research into osteoporosis.
Subjects
Sixty healthy women menopausal for less than 5 years and who had never received any medications interfering with bone metabolism.
Interventions
The 60 women were randomly allocated to 3 months therapy with either oral conjugated estrogens (0.625 mg/day) (n = 28) or transdermal estradiol (50 micrograms/day) (n = 32) in cyclical combination with medroxyprogesterone acetate (5 mg/day).
Main Outcome Measures
Traditional (urinary calcium/creatinine and hydroxyproline/creatinine) and the new specific (urinary pyridinoline/creatinine and deoxypyridinoline/creatinine) markers of bone resorption were determined before and after 3 months of treatment.
Results
In both groups, circulating levels of estrone and estradiol were significantly (P < 0.001) increased during treatment. In women treated with oral conjugated equine estrogens, urinary calcium/creatinine and hydroxyproline/creatinine ratios were significantly (P < 0.05) reduced. Pyridinoline/creatinine ratio fell from 69.1 (4) [mean (SEM)] to 50 (4) mumol/mumol (P < 0.01) and deoxypyridinoline/creatinine ratio fell from 10.8 (1) [mean (SEM)] to 8.3 (0.8) mumol/mumol (P < 0.01). In the group treated with transdermal estradiol, urinary hydroxyproline/creatinine ratio was significantly (P < 0.05) reduced. Pyridinoline/creatinine ratio fell from 66.3 (4) [mean (SEM)] to 46.2 (3) mumol/mumol (P < 0.01) and deoxypyridinoline/creatinine ratio fell from 11.5 (1.5) [mean (SEM)] to 7.7 (0.6) mumol/mumol (P < 0.01). There were no differences between the evolution of the biochemical variables in the two groups.
Conclusion
These results suggest that oral conjugated equine estrogens and transdermal estradiol, in the given doses, are equally effective in reducing postmenopausal bone resorption.
transdermal estradiol versus oral conjugated estrogen bone resorption, estrogen replacement therapy postmenopausal bone resorption markers, pyridinoline deoxypyridinoline urinary markers bone resorption menopause, oral conjugated equine estrogen bone metabolism postmenopausal, transdermal 17 beta estradiol bone resorption biochemical markers, Reginster estrogen replacement bone resorption randomized trial, medroxyprogesterone acetate estrogen cyclical therapy bone markers, postmenopausal osteoporosis prevention estrogen route comparison, urinary hydroxyproline calcium creatinine estrogen therapy, early postmenopausal estrogen therapy bone turnover markers
PMID 8394191 8394191 DOI 10.1007/BF01352008 10.1007/BF01352008
Cite this article
Reginster, J. Y., Christiansen, C., Dequinze, B., Deroisy, R., Gaspard, U., Taquet, A. N., & Franchimont, P. (1993). Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. *Calcified tissue international*, *53*(1), 13-16. https://doi.org/10.1007/BF01352008
Reginster JY, Christiansen C, Dequinze B, Deroisy R, Gaspard U, Taquet AN, et al. Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif Tissue Int. 1993;53(1):13-16. doi:10.1007/BF01352008
Reginster, Jean‐Yves Y., et al. "Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause." *Calcified tissue international*, vol. 53, no. 1, 1993, pp. 13-16.
OBJECTIVES: Bone mineral density (BMD) is a critical indicator of osteoporosis (OP). Utilizing the latest multi-omics quantitative trait loci (QTLs) data, we aim to identify novel candidates associate...
Bone Health > Bone Mineral Density > Genetic BiomarkersDiagnostics > Omics Approaches > Multi-omics IntegrationResearch Methodology > Mendelian Randomization > Bone Health